|
It was reported that a patient underwent a paroxysmal atrial fibrillation (afib) cardiac ablation procedure with a varipulse bi-directional catheter and the patient expired.After pulse field ablation (pfa) afib ablation they attempted watchman left atrial appendage occlusion (laao) device placement on 31-jul-2026, the patient developed heart failure and passed away.The pfa procedure for afib with trupulse/varipulse was unremarkable.Forty-two (42) pfa applications were delivered, carto mapping was performed with the pentaray catheter, nothing out of the ordinary occurred during the procedure and the patient was stable afterward.Varipulse plus settings of 30ml/min ablation irrigation flow rate, manual switching to 4ml/min idle, inter application delay 10 seconds were used during the procedure.After the pulmonary vein isolation (pvi) portion of the procedure the physician attempted to implant the watchman laao device.This procedure was aborted as it was determined that the patient's appendage was too large for implantation.The patient left the lab on (b)(6) in stable condition.The day following the procedure, (b)(6) 2026, the patient returned to the hospital emergency room with heart failure (previously undiagnosed) and that the patient expired on (b)(6) 2026.Cause of death is believed to be acute heart failure related but cannot be confirmed.
|
|
Device investigation details:
an analysis of the product could not be performed since a physical sample was not received for evaluation.However, if the product is received at a later date, the investigation will be updated as applicable.An evaluation of the manufacturing record could not be performed as the required product identification number was not provided to complete the evaluation.As part of our company quality system process, all devices are manufactured, inspected, and distributed to approved specifications.Note: for field d4: udi: as the lot number for the device involved in the event was not provided, the full udi is currently not available.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc., or its employees that the report constitutes an admission that the product, biosense webster inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's ref.# (b)(4.
|